HUE041509T2 - Szubsztituált nukleozidok, nukleotidok és ezek analógjai - Google Patents

Szubsztituált nukleozidok, nukleotidok és ezek analógjai

Info

Publication number
HUE041509T2
HUE041509T2 HUE12860391A HUE12860391A HUE041509T2 HU E041509 T2 HUE041509 T2 HU E041509T2 HU E12860391 A HUE12860391 A HU E12860391A HU E12860391 A HUE12860391 A HU E12860391A HU E041509 T2 HUE041509 T2 HU E041509T2
Authority
HU
Hungary
Prior art keywords
nucleotides
analogs
substituted nucleosides
nucleosides
substituted
Prior art date
Application number
HUE12860391A
Other languages
English (en)
Inventor
Leonid Beigelman
Guangyi Wang
David Smith
Jerome Deval
Marija Prhavc
Original Assignee
Janssen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669505&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE041509(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biopharma Inc filed Critical Janssen Biopharma Inc
Publication of HUE041509T2 publication Critical patent/HUE041509T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Package Frames And Binding Bands (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
HUE12860391A 2011-12-22 2012-12-20 Szubsztituált nukleozidok, nukleotidok és ezek analógjai HUE041509T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579560P 2011-12-22 2011-12-22
US201261613836P 2012-03-21 2012-03-21

Publications (1)

Publication Number Publication Date
HUE041509T2 true HUE041509T2 (hu) 2019-05-28

Family

ID=48669505

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12860391A HUE041509T2 (hu) 2011-12-22 2012-12-20 Szubsztituált nukleozidok, nukleotidok és ezek analógjai

Country Status (35)

Country Link
US (4) US9073960B2 (hu)
EP (2) EP2794627B1 (hu)
JP (2) JP6385825B2 (hu)
KR (1) KR102072041B1 (hu)
CN (2) CN107459544B (hu)
AP (1) AP2014007796A0 (hu)
AR (1) AR089408A1 (hu)
AU (2) AU2012358803C1 (hu)
BR (1) BR112014014740B1 (hu)
CA (2) CA3107640A1 (hu)
CL (1) CL2014001641A1 (hu)
CO (1) CO6990737A2 (hu)
CY (1) CY1121416T1 (hu)
DK (1) DK2794627T3 (hu)
EA (1) EA035493B1 (hu)
EC (1) ECSP14010277A (hu)
ES (1) ES2702060T3 (hu)
GE (1) GEP20166496B (hu)
HK (3) HK1203076A1 (hu)
HR (1) HRP20182096T1 (hu)
HU (1) HUE041509T2 (hu)
IL (2) IL233152B (hu)
LT (1) LT2794627T (hu)
MX (2) MX356509B (hu)
PH (2) PH12014501436B1 (hu)
PL (1) PL2794627T3 (hu)
PT (1) PT2794627T (hu)
RS (1) RS58099B1 (hu)
SG (3) SG11201402826YA (hu)
SI (1) SI2794627T1 (hu)
TW (1) TWI659963B (hu)
UA (1) UA117095C2 (hu)
UY (1) UY34536A (hu)
WO (1) WO2013096679A1 (hu)
ZA (1) ZA201404486B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AP3584A (en) 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
DK2794627T3 (en) 2011-12-22 2019-01-14 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
NZ630800A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Methods of preparing substituted nucleotide analogs
PL2827875T3 (pl) * 2012-03-21 2019-07-31 Janssen Biopharma, Inc. Podstawione nukleozydy, nukleotydy i ich analogi
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
DK2935303T3 (da) 2012-12-21 2021-05-03 Janssen Biopharma Inc 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
CA2894541A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
TWI655199B (zh) 2013-06-26 2019-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
EP3027617A4 (en) * 2013-07-31 2017-04-12 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3057976A1 (en) 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
CA2945693C (en) 2014-02-06 2020-06-16 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
JP6191989B2 (ja) * 2014-02-12 2017-09-06 学校法人東京理科大学 アデニン誘導体又はその薬理学的に許容しうる塩、その製造方法、及びその用途
WO2015200205A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
RU2017105470A (ru) * 2014-07-22 2018-08-22 Элиос Биофарма, Инк. Способы лечения парамиксовирусов
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
EP3177299A4 (en) * 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
TWI673283B (zh) * 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
US10358458B2 (en) 2014-09-26 2019-07-23 Riboscience Llc 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
ES2746105T3 (es) 2014-10-08 2020-03-04 Epigenetics Pharma Llc Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
EP3212657A4 (en) 2014-10-28 2018-04-11 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
KR20170123308A (ko) * 2014-12-26 2017-11-07 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
MX2017011655A (es) 2015-03-11 2018-04-30 Alios Biopharma Inc Compuestos de aza-piridona y usos de estos.
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN107501247A (zh) * 2016-06-14 2017-12-22 安徽贝克联合制药有限公司 一种尿嘧啶核苷类衍生物的制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
CN109890831A (zh) 2016-08-12 2019-06-14 詹森生物制药有限公司 被取代的核苷、核苷酸以及它们的类似物
JP7125144B2 (ja) 2016-09-09 2022-08-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
WO2018081449A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
AU2018312224A1 (en) 2017-07-31 2020-02-27 January Therapeutics, Inc. Organophosphate derivatives
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2021011572A1 (en) * 2019-07-18 2021-01-21 The Board Of Trustees Of The Leland Stanford Junior University Enhancing the antiviral efficacy of rna virus inhibition by combination with modulators of pyrimidine metabolism
US11708637B2 (en) * 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021195011A1 (en) * 2020-03-24 2021-09-30 Intrinsic Medicine, Inc. Immunomodulatory oligosaccharides for the treatment of viral respiratory infection
CN111892636A (zh) * 2020-08-07 2020-11-06 山东大学 一种阿兹夫定的合成方法
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2024015916A2 (en) * 2022-07-13 2024-01-18 Thomas Jefferson University 4'-alkyne-2'-deoxycytidine-based compounds and anti-cancer uses thereof

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH563405A5 (hu) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
IL51342A (en) 1977-01-27 1980-11-30 Abic Ltd Ethoxyquin derivatives,their preparation and pharmaceutical and veterinary compositions comprising them
US4230698A (en) 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
AU5118979A (en) 1978-10-16 1980-04-24 Takeda Chemical Industries Ltd. 2,6-diaminoebularines
US4652554A (en) 1982-02-22 1987-03-24 St. Jude Children's Research Hospital Nitro-substituted 1-β-D-arabinofuranosylcytosines
JPS60228497A (ja) 1984-04-27 1985-11-13 Sumitomo Chem Co Ltd 新規なアデニル酸誘導体
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
US4626526A (en) 1984-10-26 1986-12-02 Warner-Lambert Company (S)-N6 -2-hydroxypropyladenosines
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61219478A (ja) 1985-03-26 1986-09-29 Potsupuribetsuto Fastener Kk 溶接検知方法及び装置
PL144471B1 (en) 1985-04-22 1988-05-31 Polska Akad Nauk Centrum Method of obtaining novel 3',5'-cyclic adensine dithiophosphate
US4762823A (en) 1985-10-16 1988-08-09 Sloan-Kettering Institute For Cancer Research Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
US4797495A (en) 1985-11-22 1989-01-10 Burroughs Wellcome Co. Benzo[c]carbazole propanediol compound and salts thereof
KR950001023B1 (ko) 1986-04-14 1995-02-07 셀 인터나쵸나아레 레사아치 마아츠샤피 비이부이 할로겐화 헤테로시클릭 에테르 제초제 제조방법
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
SU1417408A1 (ru) 1986-12-02 1995-09-10 Г.П. Акулов Способ получения меченного тритием дезоксиаденозина
JPH0699467B2 (ja) 1987-03-04 1994-12-07 ヤマサ醤油株式会社 ２▲’▼−デオキシ−２▲’▼（ｓ）−アルキルピリミジンヌクレオシド誘導体
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
DE3730542A1 (de) 1987-09-11 1989-04-06 Hoechst Ag Arzneimittel mit einem gehalt an bestimmten 6-mercaptopurin-derivaten, verwendung dieser 6-mercaptopurin-derivate, verfahren zur herstellung der arzneimittel sowie einige neue 6-mercaptopurin-derivate und verfahren zu deren herstellung
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
HU204843B (en) 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
MX9203459A (es) 1988-11-15 1992-08-01 Merrell Pharma Inc Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
CA2002648C (en) 1988-11-15 2000-02-29 James R. Mccarthy 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
US5616702A (en) 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
NO171507C (no) 1988-11-21 1993-03-24 Syntex Inc Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater
SE462497B (sv) 1988-11-30 1990-07-02 Clas Fredrik Runesson Kaelland Saett foer att aktivitetsbestaemma polymeraser
FR2642074B1 (fr) 1989-01-20 1994-04-29 Oris Ind Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide
US5296348A (en) 1989-05-16 1994-03-22 The Wistar Institute Of Anatomy And Biology Methods for screening monoclonal antibodies for therapeutic use
DE3916871A1 (de) 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
JPH0699711B2 (ja) 1989-07-25 1994-12-07 花王株式会社 液体洗浄剤組成物
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
US5514786A (en) 1990-01-11 1996-05-07 Isis Pharmaceuticals, Inc. Compositions for inhibiting RNA activity
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
CA2037767A1 (en) 1990-03-23 1991-09-24 Mark D. Wittman Conversion of amines to hydroxylamines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5478813A (en) 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
AU7623991A (en) 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
GB9012899D0 (en) 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
JP2559917B2 (ja) 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5777100A (en) 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99125A0 (en) 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5420115A (en) * 1990-09-10 1995-05-30 Burroughs Wellcome Co. Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU665184B2 (en) 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
US5171849A (en) 1991-04-19 1992-12-15 The Ohio State University Research Foundation 2' and 3' Carboranyl uridines and their diethyl ether adducts
US5446031A (en) 1991-04-24 1995-08-29 Yamasa Shuyu Kabushiki Kaisha 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
GB9111580D0 (en) 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5192764A (en) 1991-05-30 1993-03-09 Research Foundation Of State Of N.Y. Pyrazinone n-oxide nucleosides and analogs thereof
US5508407A (en) 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
JPH0551395A (ja) 1991-08-21 1993-03-02 Teijin Ltd ペンタフルオロプロピオニル化（デオキシ）ウリジンおよびそれを用いる（デオキシ）ウリジンの測定方法
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE4131579A1 (de) 1991-09-23 1993-03-25 Boehringer Mannheim Gmbh Thiadiazolo(4,3-a)pyridinderivate, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel
CA2079413C (en) 1991-09-30 2003-09-09 Masakatsu Kaneko Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
DE637965T1 (de) 1991-11-26 1995-12-14 Gilead Sciences Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
FR2684997A1 (fr) 1991-12-12 1993-06-18 Centre Nat Rech Scient Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique.
FR2688003B1 (fr) 1992-02-28 1995-06-30 Univ Limoges Derives de nucleosides, leur preparation et leurs applications biologiques.
US5543507A (en) 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
DE69320646T2 (de) 1992-04-10 1999-01-14 Merrell Pharma Inc Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5808139A (en) 1992-04-21 1998-09-15 Ligand Pharmaceuticals Incorporated Non-steroid progesterone receptor agonist and antagonist and compounds and methods
EP0640092B1 (en) 1992-05-12 1996-12-11 Merrell Pharmaceuticals Inc. A process for the preparation of ribonucleotide reductase inhibitors
DE4217679C2 (de) 1992-05-26 1998-02-19 Genieser Hans Gottfried Dr Cyclische Guanosin-3',5'-phosphorothioat-Derivate
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
ATE299509T1 (de) 1992-07-23 2005-07-15 Isis Pharmaceuticals Inc Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
AU6449294A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Novel 5'-substituted nucleosides and oligomers produced therefrom
JP4086314B2 (ja) 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
JPH07242544A (ja) 1994-03-01 1995-09-19 Takeda Chem Ind Ltd 抗腫瘍剤
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US6004939A (en) 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
EP0879056B1 (en) 1996-01-23 2002-05-02 ICN Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes
JPH09328497A (ja) 1996-04-12 1997-12-22 Yamasa Shoyu Co Ltd ４’−フルオロメチルヌクレオシド
AU727177B2 (en) 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
PL187107B1 (pl) 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US20030064945A1 (en) 1997-01-31 2003-04-03 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
AU4322799A (en) 1998-05-28 1999-12-13 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
DE19855963A1 (de) 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
AU777049B2 (en) * 1999-03-18 2004-09-30 Qiagen Gmbh Xylo-LNA analogues
EP1178999B1 (en) * 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
JP4076114B2 (ja) 1999-05-12 2008-04-16 ヤマサ醤油株式会社 ４’−ｃ−エチニルプリンヌクレオシド化合物
DE60005501T2 (de) * 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
HUP0301875A2 (hu) 1999-08-27 2003-09-29 Icn Pharmaceuticals, Inc. Pirrolo[2,3-d]pirimidinnukleozid-származékok
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
BR0016415A (pt) 1999-12-16 2002-12-24 Alcon Inc Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
JP2002322192A (ja) * 2000-08-10 2002-11-08 Sankyo Co Ltd ２’−ｏ，４’−ｃ−架橋ヌクレオシドトリリン酸体
JP2004313002A (ja) 2000-10-12 2004-11-11 Mitsui Chemicals Inc ヌクレオシドの製造方法
WO2002031176A1 (fr) 2000-10-12 2002-04-18 Mitsui Chemicals, Inc. Procédé permettant la production de nucléosides
AU2002228749B2 (en) * 2000-10-18 2008-04-24 Pharmasset Inc Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
JP4012070B2 (ja) 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
PL207405B1 (pl) 2001-01-22 2010-12-31 Isis Pharmaceuticals Inc Pochodne nukleozydów, zawierająca je kompozycja farmaceutyczna i ich zastosowanie
JP2002302498A (ja) 2001-04-03 2002-10-18 Mitsui Chemicals Inc ヌクレオシドの工業的な製造法
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030124513A1 (en) 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2003012690A (ja) 2001-07-03 2003-01-15 Mitsui Chemicals Inc 置換イミダゾール誘導体又は置換ベンズイミダゾール誘導体を用いたヌクレオチドの製造法
JP2003055392A (ja) 2001-08-08 2003-02-26 Mitsui Chemicals Inc １−リン酸化糖の製造法並びにヌクレオシドの製造法
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
US7125982B1 (en) 2001-12-05 2006-10-24 Frayne Consultants Microbial production of nuclease resistant DNA, RNA, and oligo mixtures
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003062255A2 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
AU2003222743B2 (en) 2002-05-08 2008-12-11 Roche Innovation Center Copenhagen A/S Synthesis of locked nucleic acid derivatives
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
EP1511757B1 (en) 2002-06-07 2015-11-04 Universitair Medisch Centrum Utrecht New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
TW200500373A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7393954B2 (en) 2002-12-12 2008-07-01 Reliable Biopharmaceutical Corporation Process for the production of pentostatin aglycone and pentostatin
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
US7002006B2 (en) 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
AU2004269026B2 (en) 2003-08-27 2010-02-25 Biota Scientific Management Pty Ltd Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
CA2542077A1 (en) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7144868B2 (en) 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
ES2287804T3 (es) 2003-12-29 2007-12-16 Can-Fite Biopharma Ltd. Metodo para el tratamiento de esclerosis multiples.
DE102004009704A1 (de) 2004-02-27 2005-09-15 Dmitry Cherkasov Makromolekulare Nukleotidverbindungen und Methoden zu deren Anwendung
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
US20060040944A1 (en) 2004-06-23 2006-02-23 Gilles Gosselin 5-Aza-7-deazapurine derivatives for treating Flaviviridae
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1778239B1 (en) 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9035035B2 (en) 2004-11-05 2015-05-19 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
AU2005302090A1 (en) 2004-11-08 2006-05-11 Can-Fite Biopharma Ltd. Therapeutic treatment of accelerated bone resorption
JP2006131596A (ja) 2004-11-09 2006-05-25 Univ Nagoya ヌクレオチド及びその誘導体の製造方法
JP2008523082A (ja) * 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2007144686A1 (en) 2005-03-09 2007-12-21 Idenix (Cayman) Limited Nucleosides with non-natural bases as anti-viral agents
JP2006248949A (ja) 2005-03-09 2006-09-21 Univ Nagoya ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006116512A1 (en) 2005-04-26 2006-11-02 The Board Of Trustees Of The University Of Illinois, Urbana, Il Nucleoside compounds and methods of use thereof
WO2007006544A2 (en) 2005-07-12 2007-01-18 Vrije Universiteit Brussel Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
WO2007038860A2 (en) 2005-10-03 2007-04-12 University Health Network Odcase inhibitors as anti-virals and antibiotics
EP1947092B1 (en) 2005-11-09 2015-04-15 Tosoh Corporation Method for producing nucleic acid base having perfluoroalkyl group
CN101410407A (zh) 2006-04-03 2009-04-15 阿斯利康(瑞典)有限公司 取代腺嘌呤及其应用
WO2007149554A2 (en) 2006-06-22 2007-12-27 The Johns Hopkins University Methods for restoring neural function
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
EA201501088A1 (ru) 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
DE102006037786A1 (de) 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008086042A2 (en) 2007-01-10 2008-07-17 Chisari Francis V Preventing infection by a measles or respiratory syncytial virus
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
US7838234B2 (en) 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
AU2008210411A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
JP2008214305A (ja) 2007-03-07 2008-09-18 Kotobuki Seiyaku Kk 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
WO2008117046A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo [4, 3-d] pyrimidines as antibacterial compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080255038A1 (en) 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
ES2530763T3 (es) 2007-06-25 2015-03-05 Anadys Pharmaceuticals Inc Procedimiento continuo de hidrólisis enzimática
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
PL2227234T3 (pl) 2007-10-15 2014-11-28 Can Fite Biopharma Ltd Sposób wywoływania proliferacji hepatocytów i jego zastosowania
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
US20090181921A1 (en) 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
CN102083828B (zh) 2008-02-22 2013-11-13 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
US8445669B2 (en) * 2008-04-10 2013-05-21 Hamari Chemicals, Ltd. Production process of ethynylthymidine compounds from 5-methyluridine as a starting material
US8513205B2 (en) 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
EP2268288A4 (en) 2008-04-15 2012-05-30 Rfs Pharma Llc NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
DE102008035299A1 (de) 2008-07-29 2010-02-04 Resprotect Gmbh Konjugat aus Hsp27 und einem Nukleosid, Verfahren zur Phosphorylierung von Hsp27 und Verwendung zur Herstellung eines Arzneimittels
GB0815315D0 (en) 2008-08-21 2008-09-24 Univ Leiden Organ protection
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
EP2332953A1 (en) 2008-09-05 2011-06-15 Kotobuki Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition comprising same as the active ingredient
WO2010030858A1 (en) * 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
JP2012513953A (ja) 2008-09-23 2012-06-21 アルニラム ファーマスーティカルズ インコーポレイテッド 付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾
CN102264374B (zh) 2008-10-24 2015-01-07 Isis制药公司 5′和2′双取代的核苷和由其制备的低聚化合物
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
AU2010221419B2 (en) * 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
AU2010226466A1 (en) 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
AU2010249119A1 (en) 2009-05-12 2011-12-01 Southern Research Institute 2'-fluoro arabino nucleosides and use thereof
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
KR101701510B1 (ko) 2010-07-09 2017-02-01 엘지이노텍 주식회사 발광소자
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
JP5640552B2 (ja) 2010-08-23 2014-12-17 セイコーエプソン株式会社 制御装置、表示装置及び表示装置の制御方法
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
AP3584A (en) 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
SI2646444T1 (sl) 2010-12-03 2016-09-30 Epizyme, Inc. Substituirane spojine purina in 7-deazapurina kot modulatorji epigenetskih encimov
CA2819041A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
DK2794627T3 (en) 2011-12-22 2019-01-14 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF
US9453014B2 (en) 2011-12-22 2016-09-27 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof
CN104125960A (zh) 2011-12-22 2014-10-29 康内克斯生命科学私人有限公司 氮杂金刚烷的衍生物及其用途
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
BR112014015103B1 (pt) 2011-12-22 2022-06-28 Novartis Ag Derivados de di-hidro-benzo-oxazina e di-hidro-pirido-oxazina, seus usos, combinação e composição farmacêutica
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
CN106749272B (zh) 2012-03-13 2019-08-30 吉利德科学公司 用于抗病毒治疗的2’-取代的卡巴-核苷类似物
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
PL2827875T3 (pl) 2012-03-21 2019-07-31 Janssen Biopharma, Inc. Podstawione nukleozydy, nukleotydy i ich analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630800A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Methods of preparing substituted nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
US20150183818A1 (en) 2012-07-03 2015-07-02 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014022639A1 (en) 2012-08-01 2014-02-06 Vertex Pharmaceuticals Incorporated Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
JP6533896B2 (ja) 2012-09-04 2019-06-26 株式会社ダナフォーム 化合物、核酸、標識物質および検出方法
JP6276769B2 (ja) 2012-09-26 2018-02-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐａｒｐインヒビターとしてのキナゾリノン誘導体
AU2013322736A1 (en) 2012-09-26 2015-02-26 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX2015005500A (es) 2012-10-29 2016-02-09 Cocrystal Pharma Inc Nucleotidos de pirimidina y sus profarmacos de monofosfato para el tratamiento de infecciones virales y cancer.
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
DK2935303T3 (da) 2012-12-21 2021-05-03 Janssen Biopharma Inc 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
CA2894541A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20140309413A1 (en) 2013-03-11 2014-10-16 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
TWI655199B (zh) 2013-06-26 2019-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3160979A4 (en) 2014-06-24 2018-01-03 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2015200205A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
RU2017105470A (ru) 2014-07-22 2018-08-22 Элиос Биофарма, Инк. Способы лечения парамиксовирусов
EP3177299A4 (en) 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
US9981175B2 (en) 2014-09-12 2018-05-29 Dan DeLaRosa Taekwondo bag
EP3212657A4 (en) 2014-10-28 2018-04-11 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN109890831A (zh) 2016-08-12 2019-06-14 詹森生物制药有限公司 被取代的核苷、核苷酸以及它们的类似物
WO2018081449A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection

Also Published As

Publication number Publication date
CO6990737A2 (es) 2014-07-10
EA201491040A1 (ru) 2015-01-30
EP3466959A1 (en) 2019-04-10
BR112014014740B1 (pt) 2021-08-24
AU2012358803B2 (en) 2018-02-15
AU2018203423A1 (en) 2018-06-07
EA035493B1 (ru) 2020-06-25
JP2015503506A (ja) 2015-02-02
AU2012358803A1 (en) 2014-08-07
ES2702060T3 (es) 2019-02-27
CN107459544A (zh) 2017-12-12
CA2860289A1 (en) 2013-06-27
KR20140108287A (ko) 2014-09-05
UA117095C2 (uk) 2018-06-25
US9073960B2 (en) 2015-07-07
PT2794627T (pt) 2018-12-19
CY1121416T1 (el) 2020-05-29
SG10201913554YA (en) 2020-03-30
EP2794627B1 (en) 2018-09-26
SG11201402826YA (en) 2014-12-30
TW201333027A (zh) 2013-08-16
US11021509B2 (en) 2021-06-01
IL233152A0 (en) 2014-07-31
SI2794627T1 (sl) 2019-02-28
CN104114568A (zh) 2014-10-22
AP2014007796A0 (en) 2014-07-31
UY34536A (es) 2013-07-31
BR112014014740A8 (pt) 2017-07-04
AU2018203423B2 (en) 2020-04-30
BR112014014740A2 (pt) 2017-06-13
CA2860289C (en) 2021-03-16
HK1203204A1 (en) 2015-10-23
US20200024297A1 (en) 2020-01-23
PH12014501436A1 (en) 2014-10-08
JP6385825B2 (ja) 2018-09-05
US10464965B2 (en) 2019-11-05
LT2794627T (lt) 2019-01-10
US20150315228A1 (en) 2015-11-05
HK1203076A1 (en) 2015-10-16
CL2014001641A1 (es) 2014-12-12
JP6718487B2 (ja) 2020-07-08
ZA201404486B (en) 2022-03-30
SG10201610936RA (en) 2017-02-27
CN107459544B (zh) 2021-03-16
MX356509B (es) 2018-05-30
WO2013096679A1 (en) 2013-06-27
CA3107640A1 (en) 2013-06-27
CN104114568B (zh) 2017-09-01
RS58099B1 (sr) 2019-02-28
EP2794627A1 (en) 2014-10-29
EP2794627A4 (en) 2015-04-29
KR102072041B1 (ko) 2020-01-31
PL2794627T3 (pl) 2019-04-30
JP2018188468A (ja) 2018-11-29
IL233152B (en) 2020-03-31
IL272953B (en) 2021-10-31
IL272953A (en) 2020-04-30
US20210179656A1 (en) 2021-06-17
NZ627179A (en) 2016-07-29
MX2014007480A (es) 2014-07-30
MX2018006658A (es) 2021-12-08
DK2794627T3 (en) 2019-01-14
TWI659963B (zh) 2019-05-21
PH12015502273A1 (en) 2017-12-11
AU2012358803C1 (en) 2019-12-19
ECSP14010277A (es) 2015-08-31
US20130165400A1 (en) 2013-06-27
PH12014501436B1 (en) 2014-10-08
HK1248239A1 (zh) 2018-10-12
HRP20182096T1 (hr) 2019-02-22
GEP20166496B (en) 2016-06-27
AR089408A1 (es) 2014-08-20

Similar Documents

Publication Publication Date Title
IL272953B (en) Nucleosides, modified nucleotides and their analogs
IL274901A (en) Nucleosides, modified nucleotides and their analogs
HRP20182030T1 (hr) Supstituirani nukleozidi, nukleotidi i njihovi analozi
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
HK1224229A1 (zh) 取代的核苷，核苷酸及其類似物
HK1222178A1 (zh) 取代的核苷、核苷酸及其類似物
IL245014A0 (en) Nucleosides, modified nucleotides and their analogs